ASH 2022 Conference Coverage

Login

Password

Forgot your password?

Join VuMedi

Select specialty

First name

Last name

Choose Password

About Us
Careers
Partner with us
F.A.Q
Contact us
Terms & conditions
Privacy policy

ASH 2022 Conference Coverage

Lymphoma
Leukemia
Myeloma
MDS and MPN
Benign Hematology

Video Player is loading.

Current Time 0:00

Duration 0:00

Loaded: 0%

Stream Type LIVE

Remaining Time -0:00

0.5x
0.75x
1x, selected
1.25x
1.5x
1.75x
2x

Chapters

descriptions off, selected

captions settings, opens captions settings dialog
captions off, selected

This is a modal window.

Beginning of dialog window. Escape will cancel and close the window.

TextColorTransparency

BackgroundColorTransparency

WindowColorTransparency

Font Size

Text Edge Style

Font Family

End of dialog window.

10 seconds

Playback speed

This is a modal window. This modal can be closed by pressing the Escape key or activating the close button.

ASH 2022 Impact of Allelic State on Overall Survival in TP53-Mutant AML and HR-MDS

By ASH 2022 Conference Coverage FEATURING Jan Bewersdorf

97 views

December 16, 2022

Comments 0

MDS and MPN

Ropeginterferon Alfa-2b vs. Standard Therapy for Low-Risk Pts With P…

ASH 2022 Conference Coverage

T. Barbui

188 views

MEDALIST Study: Multiple Episodes of Transfusion Independence With L…

ASH 2022 Conference Coverage

U. Platzbecker

194 views

Selected Updates in MDS

ASH 2022 Conference Coverage

A. Zeidan

491 views

Phase 2 FIGHT-203 Study: Pemigatinib in Pts With Myeloid/Lymphoid Ne…

ASH 2022 Conference Coverage

A. Vannucchi

439 views

MAJIC-PV Trial: Ruxolitinib vs. Best Available Therapy for PV Intole…

ASH 2022 Conference Coverage

M. McMullin

1.2K views

ASH 2022: Venetoclax Combined With Cladribine, Idarubicin, Cytarabin…

ASH 2022 Conference Coverage

G. Borthakur

180 views

ASH 2022 Real-World Validation of Molecular International Prognostic…

ASH 2022 Conference Coverage

M. Della Porta

49 views

ASH 2022: Management of Accelerated and Blast-Phase MPN

ASH 2022 Conference Coverage

R. Rampal

62 views

ASH 2022: Navitoclax and Ruxolitinib in JAKi-Naïve Patients With MF …

ASH 2022 Conference Coverage

F. Passamonti

81 views

ASH 2022: What Is Complete HLA Match in 2022?

ASH 2022 Conference Coverage

S. Spellman

196 views

ASH 2022 Outcomes of Patients With Accelerated/Blast-Phase MPNs in t…

ASH 2022 Conference Coverage

A. Patel

111 views

ASH 2022 Phase II Study of Myeloablative 8/8- or 7/8-Matched AlloSCT…

ASH 2022 Conference Coverage

A. Hoover

34 views

Synergistic Activity of Luspatercept and Erythroid Stimulating Agent…

ASH 2022 Conference Coverage

R. Komrokji

286 views

Luspatercept for Treatment of LR-MDS: Real World Data Replicates MED…

ASH 2022 Conference Coverage

R. Komrokji

337 views

ASH 2022 Phase 1 Results of the First-in-Class CXCR1/2 Inhibitor SX-…

ASH 2022 Conference Coverage

D. Sallman

44 views

ASH 2022 Primary Results of STIMULUS-MDS1: A Randomized, Double-Blin…

ASH 2022 Conference Coverage

A. Zeidan

135 views

Phase 3b, Single-Arm, Multicenter Study to Assess the Efficacy, Safe…

ASH 2022 Conference Coverage

J. Mascarenhas

137 views

Validation of 2022 WHO & ICC Classifications in MDS - An Analysis on…

ASH 2022 Conference Coverage

S. Ball

196 views

ASH 2022 Results From Phase III BMT CTN 1703: Post-Transplant Cyclop…

ASH 2022 Conference Coverage

S. Holtan

355 views

ASH 2022 Efficacy & Safety of Add-On Parsaclisib to Ruxolitinib Ther…

ASH 2022 Conference Coverage

A. Yacoub

61 views

ASH 2022 Impact of Allelic State on Overall Survival in TP53-Mutant …

ASH 2022 Conference Coverage

J. Bewersdorf

97 views

Updated Results From the Momentum Phase 3 Study of Momelotinib vs. D…

ASH 2022 Conference Coverage

A. Gerds

236 views